trydonis
chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).
seebri breezhaler 50 mcg
novartis israel ltd - glycopyrronium as bromide - inhalation powder hard capsules - glycopyrronium as bromide 50 mcg - glycopyrronium - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).
breztri aerosphere aerosol, metered dose
astrazeneca canada inc - budesonide; glycopyrronium (glycopyrronium bromide); formoterol fumarate dihydrate - aerosol, metered dose - 160mcg; 7.2mcg; 5mcg - budesonide 160mcg; glycopyrronium (glycopyrronium bromide) 7.2mcg; formoterol fumarate dihydrate 5mcg - antimuscarinics antispasmodics
xoterna breezhaler 110/50mcg inhalation powder hard capsule
alcon laboratories (malaysia) sdn. bhd. - indacaterol maleate; glycopyrronium bromide -
atectura breezhaler 125/260 indacaterol (as acetate)/mometasone furoate 125/260 microgram powder for inhalation in hard capsule with inhaler
novartis pharmaceuticals australia pty ltd - indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram); mometasone furoate, quantity: 320 microgram - capsule, hard - excipient ingredients: lactose monohydrate - atectura breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists
seebri breezhaler
novartis pharmaceuticals australia pty ltd - glycopyrronium bromide -
brimica genuair 340/12 aclidinium bromide and formoterol fumarate dihydrate powder for inhalation dry powder inhaler
a menarini australia pty ltd - aclidinium bromide, quantity: 0.4 mg/actuation; formoterol fumarate dihydrate, quantity: 0.012 mg/actuation - inhalation, powder for - excipient ingredients: lactose monohydrate - brimica genuair 340/12 is indicated as a long-term twice daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).
arcapta neohaler indacaterol maleate capsule
novartis pharmaceuticals corporation - indacaterol maleate (unii: 2jec1itx7r) (indacaterol - unii:8or09251mq) - indacaterol 75 ug
enerzair breezhaler , inhalation powder , hard capsule 160 mcg/1 cap, 150 mcg/1 cap, 50 mcg/1 cap
شركة مستودع الأدوية الأردني - the jordan drugstore co - mometasone furoate 160 mcg/1 cap, indacaterol 150 mcg/1 cap, glycopyrronium bromide 50 mcg/1 cap - 160 mcg/1 cap, 150 mcg/1 cap, 50 mcg/1 cap
ultibro breezhaler
novartis sa (pty) ltd - indacaterol maleate and glycopyrronium bromide - dry powder inhalation capsules - each capsule contains indacaterol maleate equivalent to 110 micrograms indacaterol and glycopyrronium bromide equivalent to 50 m